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Abstract
Oral lichen planus (OLP) is an immune- mediated disease of the oral mucosa with 
idiopathic aetiology. It is frequently treated with topical corticosteroids (applied as 
gels, mouthwashes, or sprays); however, the mucosal exposure times of topical corti-
costeroids are short because of removal by the constant flow of saliva and mechanical 
forces. In this study we used cell monolayers, as well as oral mucosal equivalents 
(OMEs) containing activated T- cells, to examine corticosteroid potency and deliv-
ery of clobetasol- 17- propionate from a novel electrospun mucoadhesive patch. The 
OMEs displayed tight junctions, desmosomes, hemidesmosomes, and an efficient 
permeability barrier. Following application of corticosteroids to cells cultured as 
monolayers, the degree of cytotoxicity measured correlated to the level of potency 
recognized for each corticosteroid; by contrast, OMEs were largely unaffected by 
corticosteroid treatment. Permeation of clobetasol- 17- propionate into and through the 
OMEs was time- and dose- dependent, regardless of whether this corticosteroid was 
delivered in liquid form or from a mucoadhesive patch, and both liquid- and patch- 
delivered clobetasol- 17- propionate significantly reduced the secretion of interleukin-
 2 by activated T- cells. This study confirms that OMEs are more suitable models than 
cell monolayers for evaluating toxicity and drug delivery. After topical exposure, 
clobetasol- 17- propionate accumulated in OMEs at a higher level than betamethasone- 
17- valerate and hydrocortisone- 17- valerate, and exerted its immunosuppressive ac-
tions following application via the patch delivery system, highlighting the efficacy of 
this mode of drug delivery to treat OLP.
K E Y W O R D S
drug delivery, inflammation, mouth mucosa, oral lichen planus, T- lymphocytes
Oral lichen planus (OLP) and other closely related li-
chenoid lesions specifically affect the stratified squamous 
epithelium of the oral mucosa (1) and are relatively com-
mon, affecting 1%– 2% of the world's population, with 
prevalence increasing with age (2). Clinically, OLP most 
commonly presents on the buccal mucosa, gingivae, and 
lateral tongue as white papules or plaques that form re-
ticular striations, with erythema, erosion, and ulceration 
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frequently associated (1,3). Histological diagnosis is based 
on the presence of a dense mononuclear leukocyte infiltrate 
in the superficial lamina propria, predominantly containing 
CD4- helper and CD8+ T- lymphocytes, along with hyper-
keratosis, atrophy of the epithelium, and degeneration of 
the basement membrane (4,5).
The exact aetiology of OLP is idiopathic, and pathogen-
esis is mediated by dysregulated cell- mediated immunity. 
Immunopathogenesis is initiated by activation of antigen- 
presenting cells, most likely through antigen uptake by 
Langerhans cells, although macrophages have also been 
implicated. Increased local secretion of pro- inflammatory 
mediators triggers release of the lymphocyte- recruiting C- 
X- C motif chemokines (CXCL) 9, 10, and 11, and the C- C 
motif chemokine 5 (CCL5), all of which attract T- cell sub-
sets into the developing lesion. Antigen- presenting cells 
and oral keratinocytes present antigen to CD4+ and CD8+ 
T- cells whereupon activated helper CD4+ T- lymphocytes 
secrete IL- 2, IL- 12 and IFN- γ, promoting receptor- 
mediated activation of cytotoxic CD8+ T- cells that in turn 
mediate apoptosis of basal keratinocytes causing pathol-
ogy. Increasing evidence suggests that other T- lymphocyte 
subsets, such as regulatory T- cells, T- helper 17 cells, and 
mucosal- associated invariant T- cells, are also implicated in 
OLP pathogenesis, while mast cell degranulation releases 
matrix metalloproteases and chymase, leading to basement 
membrane degradation that aids further recruitment of 
lymphocytes (6).
Symptomatic treatment options are mainly dependent on 
topical application of immune- modulating corticosteroids, 
including triamcinolone acetonide and betamethasone- 17- 
valerate, or halogenated forms of corticosteroid (such as 
clobetasol- 17- propionate), whereas systemically delivered 
prednisolone is often the choice for severe lesions that do 
not respond to topical therapy (1,7). Topical corticosteroids 
have been formulated into ointments, sprays, mouthwashes, 
and adhesive paste dosage forms (8- 11), although these are 
generally considered to be suboptimal as a result of rapid re-
moval of such formulations from the lesion site by saliva flow 
and mechanical forces, culminating in short exposure times 
and unpredictable drug distribution. To circumvent this, at-
tention has been focussed on the development of alternative 
mucoadhesive oral drug- delivery systems (12- 16). Indeed, 
we recently reported the fabrication of a novel dual- layer 
electrospun mucoadhesive system, composed of a highly mu-
coadhesive inner layer and a protective, outer backing layer, 
specifically designed for oral mucosal drug delivery (17).
The development of new drug- delivery devices has been 
hampered by the lack of in vitro model systems that accu-
rately mimic the human oral mucosa. Oral mucosal equiv-
alents (OMEs) based on the TR146 metastatic oral cancer 
cell line have previously been used but, in contrast to native 
oral mucosa, these malignant epithelial cells do not stratify 
and display altered cytokeratin profiles (18). Oral muco-
sal equivalents composed of normal oral keratinocytes and 
fibroblasts have been produced and used to evaluate drug 
delivery (19) but these models require access to primary 
cells that have a limited lifespan, so their use is restricted. 
We recently developed a full- thickness OME based on im-
mortalized oral keratinocytes and showed that this OME 
displayed a high degree of similarity to native tissue in 
terms of histological structure and marker expression (20), 
although detailed information about its barrier properties 
has yet to be provided.
This study aimed to characterize our previously estab-
lished OME for barrier function and usefulness in drug 
delivery, and then to examine the potency of several cor-
ticosteroids in both two- and three- dimensional culture 
systems. We subsequently compared topical delivery and 
activity of clobetasol- 17- propionate from a mucoadhesive 
electrospun patch and when administered in liquid form, 
on an in vitro OLP- like model consisting of OMEs with 
activated T- cells.
MATERIAL AND METHODS
All reagents were purchased from Sigma- Aldrich and used 
according to the manufacturer’s instructions, unless other-
wise stated.
Cell culture
Immortalized buccal keratinocytes (FNB6- TERT; Ximbio) 
(21) were cultured in flavin- and adenine- enriched medium 
(22) and used from passages 10– 20. Normal oral fibroblasts 
(NOFs) isolated from the buccal mucosa of a 34- yr- old fe-
male non- smoker, who had given written, informed con-
sent (ethical approval number 09/H1308/66), were cultured 
in Dulbecco's modified Eagle's medium (DMEM) supple-
mented with 10% (v/v) fetal bovine serum (FBS), 2  mM 
L- glutamine, 100 IU ml– 1 penicillin, and 100 μg ml– 1 of strep-
tomycin. Jurkat E6- 1 lymphocytes (American Type Culture 
Collection) were cultured in flavin- and adenine- enriched 
medium without hydrocortisone. Jurkat cells were activated 
by treatment with phytohaemagglutinin (PHA) (5  µg  ml– 1) 
and phorbol  12- myristate- 13- acetate (PMA) (100  ng  ml– 1) 
for 24 h prior to use.
Oral mucosal equivalents
The OMEs were constructed as previously described (20). 
Briefly, freeze- dried rat- tail collagen (5 mg ml– 1), dissolved 
in 0.1 M acetic acid, was reconstituted in 10% (v/v) FBS, 10 × 
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DMEM, 2 mM L- glutamine, and reconstitution buffer (2.2% 
sodium bicarbonate, 4.8% HEPES, 0.248% NaOH in deion-
ized H20) and the pH was adjusted to 7.4 to give a final colla-
gen concentration of 3.5 mg ml–1. Then, 2.5 × 105 NOFs ml– 1 
were added to the collagen solution and 1 ml was transferred 
to 12- mm- diameter, 0.4 μm pore size, cell culture transwell 
inserts (Millipore) and incubated at 37°C for 2 h to allow the 
collagen to gel before being submerged in flavin- and adenine- 
enriched medium and incubated for 2 d at 37°C. FNB6- TERT 
keratinocytes (2.5 × 105 cells per model) were seeded onto 
the surface of the NOF- populated collagen gel and incubated, 
submerged, for a further 5 d at 37°C. Oral mucosal equiva-
lents were then raised to an air- to- liquid interface at 37°C, in 
an atmosphere of 5% CO2, and cultured for 10 d at the same 
temperature and atmosphere, with a change in medium every 
2 d. To generate a T- cell inflammatory OME, 2 × 106Jurkat 
cells activated (as described in the previous paragraph) for 
24 h with PHA and PMA were added to the basolateral com-
partment of the transwell before use in experiments.
Histological and immunohistochemical analyses
For histological analysis, OMEs were fixed in 10% nuetral- 
buffered formalin overnight and subjected to routine histo-
logical processing. Formalin- fixed, paraffin- embedded oral 
mucosal tissue was used as a control; ethical approval was 
granted by the Sheffield Research Ethics Committee (Ref: 
07/H1309/105). For immunohistochemistry, tissue sections 
(5 µm in thickness) were dewaxed, rehydrated through a series 
of alcohol dilutions, then incubated for 20 min in 3% hydrogen 
peroxide in methanol to neutralize endogenous peroxidases. 
Antigen retrieval was achieved using 0.01  M citrate buffer 
(pH 6) at high temperature. Following blocking with normal 
goat serum for 20  min, sections were incubated with anti- 
claudin 4 (EPRR17575; 1:4000), anti- E- cadherin (HECD- 1; 
1:200), or IgG isotype control primary antibodies for 1 h at 
20°C. Secondary antibody and avidin– biotin complex (ABC) 
(Vectastain Elite ABC kit; Vector Laboratories) were used 
in accordance with the manufacturer's instructions. Finally, 
3’- diaminobenzidine tetrahydrochloride (DAB; Vector 
Laboratories) was used to visualize peroxidase activity and 
the sections were counterstained with Harris's haematoxylin.
Transmission electron microscopy analysis
The OMEs were cut into 2 mm thick sections and fixed in 3% 
glutaraldehyde diluted in 0.1 M cacodylate buffer, at pH 7.4, 
for 2 h at 4°C before rinsing twice in 0.1 M phosphate buffer 
(pH 7.4) at 4°C. Then, the OME sections were post- fixed in 
2% osmium tetroxide for 2 h at room temperature, rinsed in 
0.1  M phosphate buffer, dehydrated in an ethanol gradient 
with propylene oxide for 15 min at 20°C, and incubated in 
propylene oxide/araldite resin (1:1; v/v) overnight. The fol-
lowing day, excess resin mixture was removed by evapora-
tion for 1 h, after which the OME sections were incubated 
in 100% araldite resin for 6 h and then embedded in fresh 
araldite resin for 72 h, all at 20°C. Sections (70– 90 nm in 
thickness) were stained with 3% uranyl acetate and Reynold's 
lead citrate. The sections were examined using an FEI Tecnai 
TEM at an accelerating voltage of 80 kV and images were 
taken using a Gatan digital camera.
OME viability
Analysis of cell metabolism using alamarBlue 
(ThermoFisher Scientific) was used as a surrogate meas-
urement for OME viability. alamarBlue solution (10% 
[v/v] in flavin- and adenine- enriched medium) was added 
to each insert and incubated for 5 h, after which the fluo-
rescence intensity of the medium was measured using an 
excitation wavelength of 550  nm and an emission wave-
length of 590 nm.
Transepithelial electrical resistance analysis
Oral mucosal equivalents were pre- incubated for 15  min 
in PBS to stabilize the electrical condition of the cells. 
Then, transepithelial electrical resistance (TEER) val-
ues were measured using an Epithelial Volt Ohm Meter 
(World Precision Instruments) following Ohm's (Ω) law. 
The TEER across the OME was obtained by subtract-
ing the TEER value derived from a blank transwell. An 
OME treated with 5% SDS was used as a positive control. 
Epithelial resistance (Ω  cm– 2) was calculated using the 
equation: TEER = Resistance (Ω)  ×  tissue surface area 
(cm2) (23).
OME permeability
Fluorescently- labelled dextrans (Thermofisher Scientific) 
with molecular mass values of 3, 10, and 70 kDa (250 µg ml– 1 
in Hanks’ balanced salt solution) were added to the epithelial 
surface of OMEs and incubated at 37°C in an atmosphere 
of 5% CO2. Oral mucosal equivalents treated with PBS or 
5% SDS acted as negative and positive controls, respectively. 
After 1 h, the amount of dextran in the basolateral compart-
ment was measured using a spectrometer with excitation at 
495, 548, and 590 nm and emission at 525, 578, and 620 nm, 
respectively. Permeability was calculated by determining the 
percentage of total dextran in the basolateral compartment 
normalized to blank inserts.
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Cytotoxicity of corticosteroids on oral 
keratinocytes, fibroblasts, and OMEs
The cytotoxic effects of seven corticosteroids – hydrocortisone- 
17- butyrate (HB), hydrocortisone- 17- valerate (HV), triam-
cinolone acetonide (TA), betamethasone- 17- valerate (BV), 
betamethasone- 17,21- dipropionate (BD), budesonide (BU), 
and clobetasol- 17- propionate (CP) (0.01– 500 µM) – on FNB6 
and NOF (5 × 104 cells per well) monolayers were assessed by 
determining the half maximal inhibitory concentration (IC50) 
at 72 h using an MTT assay, as previously described (24). The 
cytotoxicity of CP, BV, and HV on OMEs was evaluated ac-
cording to the Organization for Economic Co- operation and 
Development guidelines, as described previously (25).
Mucoadhesive patch formulations
Mucoadhesive patches (a kind gift from AFYX Therapeutics) 
were manufactured as previously described (17). Briefly, patches 
were fabricated by electrospinning polyvinylpyrrolidone (BASF, 
UK), Eudragit RS100 (Evonik Industries, Germany), and polyeth-
ylene oxide with a polycaprolactone backing layer (both Sigma- 
Aldrich, UK). Thereafter, CP was loaded at 1, 5, or 20 µg per patch.
Evaluation of corticosteroid permeation 
through OMEs
The OME- and OLP- like models were exposed to topical 
corticosteroids (in either liquid or patch formulations) and in-
cubated for up to 24 h. After exposure, the receptive media in 
the lower well of the transwell chamber was collected and the 
models were washed, weighed, disaggregated in collagenase 
(2 mg ml– 1), and centrifuged at 500 g for 5 min. The superna-
tants were collected and the presence of corticosteroids was 
determined using high performance liquid chromatography 
(HPLC). The concentration of corticosteroid recovered in the 
models was calculated by normalizing to the weight of the 
tissue and is expressed as nM mg– 1 of tissue.
High performance liquid chromatography
Media and tissue analyses were performed with a 
Waters 2690 HPLC instrument, using a Zorbax RX- C18 
250 mm × 4.6 mm column and a mobile phase composed of 
acetonitrile (ACN)/water: CP and BV (45% ACN in water 
for 15 min, increasing to 100% ACN after 16 min) and HV 
(40% ACN in water for 20 min, increasing to 100% ACN 
after 30 min), all at 1 ml min– 1. Emission of UV light was 
detected using a Waters 486 UV detector at 240 nm (for CP 
and BV) and 244  nm (for HV) and the concentrations of 
these corticosteroids was calculated from standard calibra-
tion curves.
Enzyme- linked immunosorbent assay
At each study time point, 500 µl of medium from the baso-
lateral compartment was removed from MOE- containing ac-
tivated T- cells and replaced with 500  µl of fresh medium. 
The samples were centrifuged (500 g, 5 min) and secretion of 
IL- 2 was evaluated using ELISA (OptEIA; BD Bioscience), 
according to the manufacturer's instructions.
Statistics
All data are expressed as mean  ±  SD of at least three in-
dependent experiments performed in triplicate technical 
repeats, unless otherwise stated. Statistical analysis was un-
dertaken using GraphPad Prism (v9.0, GraphPad Software). 
Pairwise comparisons were performed using the Student’s 
t- test, and group- wise comparisons were performed using 
one- way ANOVA with Tukey's multiple comparisons test. 




Full- thickness, tissue- engineered OMEs were generated 
using immortalized buccal keratinocytes (FNB6- TERT). 
Histological analysis revealed that on day 10, the OMEs pro-
duced a multilayered, stratified epithelium, approximately 
210 µm in thickness. Immunohistochemistry analyses demon-
strated that cell membranes throughout the epithelium stained 
positive for E- cadherin and claudin- 4, and that the nucleus 
of keratinocytes also stained positive for claudin- 4, reflecting 
F I G U R E  1  Characterization of oral mucosal equivalents (OMEs). Representative images of normal oral mucosa (A– C) and OMEs (D– F) stained 
using haematoxylin and eosin (H&E) (A, D) and immunohistochemically for E- cadherin (B, E) and claudin- 4 (C, F) (scale bar = 100 µm). Transmission 
electron micrographs of the cellular ultrastructure of an OME show desmosomes (black arrows) (G) and a hemidesmosome (white arrow) (H) (scale  
bar = 500 nm). The viability and integrity of OMEs was assessed, over 30 d in culture, using a metabolic activity assay (alamarBlue) (I) and 
transepithelial electrical resistance (TEER) (J). Permeability was measured by evaluating permeation of 3- , 10- , and 70- kDa dextrans applied topically 
to the models for 1 h (control) compared to treatment with 5% SDS (K) and by using TEER (L). Data are expressed as mean ±SD of three independent 
experiments. Statistics were performed using the Student's t- test; *P < 0.05 and **P < 0.01.
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the findings observed in vivo (Figure 1A- F). Further examina-
tion of the cellular ultrastructure using transmission electron 
microscopy identified desmosomes and hemidesmosomes 
(Figure 1G,H), confirming the presence of cell– cell and 
cell– basement membrane attachments. Metabolic activity 
of the models increased over the first 15 d in culture before 
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slowly decreasing until day 30 (Figure 1I). This was consist-
ent with TEER, which increased from 92  ±  7.1  Ω  cm– 2on 
day 5 to 156 ± 11 Ω cm– 2 on day 20, before decreasing to 
114  ±  4.7Ω  cm– 2 on day  30 (Figure 1J). Barrier proper-
ties were further tested using fluorescent dextran. After 1 h 
of incubation, OMEs demonstrated permeability of only 
36 ± 12%, 29 ± 16%, and 15 ± 7% for the 3- , 10- , and 70- 
kDa dextrans, respectively. However, for OMEs treated with 
5% SDS a significant increase of permeability, to 84 ± 11%, 
74 ± 15%, and 61 ± 23% for the 3- , 10- , and 70- kDa dextrans, 
respectively, was observed (Figure 1K), and a reduction in 
TEER from 151 ± 39 to 33 ± 8 Ω cm– 2 (Figure 1L).
In vitro cytotoxicity of commonly used 
corticosteroids
To determine the in vitro cytotoxicity of corticosteroids, oral 
keratinocytes (FNB6) were exposed to seven commonly used 
corticosteroids, and the IC50 of each corticosteroid was meas-
ured 72 h after exposure. The cytotoxicity (in order from high 
to low) was: CP>BU>BD>BV>TA>HV>HB. A similar pat-
tern was seen for NOFs, of: CP>BD>BV>BU>HB>TA>HV 
(Table 1). The toxicities of CP, BV, and HV were further 
tested using OMEs, and their IC50 values were all found to 
be greater than 400 nM. Corticosteroids with high, medium 
and low cytotoxicity – CP, BV, and HV, respectively – were 
selected for use in further experiments.
Corticosteroid permeation into OMEs
Next, CP, BV, or HV (5 μM) were delivered topically to the 
OMEs and the concentration that accumulated in the tissue and 
receptive medium after 1 h was determined by HPLC. We found 
that CP accumulated in tissue at a significantly higher level 
(2.6 ± 0.3 nM mg– 1) than either BV or HV (0.3 nM mg– 1) (Figure 
2A). By contrast, HV was found to permeate through the models 
and accumulate in receptive medium at a significantly higher 
concentration (215 ± 41 nM) than either BV (85 ± 21 nM) or 
CP (111 ± 13 nM) (Figure 2B). As a result of high levels of ac-
cumulation in tissue, CP was used in further experiments.
Delivery of CP from mucoadhesive patch 
into OME
To control corticosteroid delivery into the oral mucosa, CP 
was loaded into mucoadhesive patches at 1, 5, or 20 µg, ap-
plied topically to the OME for 1  h, then the levels of CP 
in tissue and receptive media were determined by HPLC. 
A dose– response effect was observed, with 0.05  ±  0.03, 
0.09 ± 0.03, and 0.19 ± 0.1 nM mg– 1 of CP accumulating 
in the tissue after delivery from patches containing 1, 5, or 
20  µg of CP, respectively (Figure 3A). Only CP released 
from the patch containing 20  µg of this corticosteroid was 
T A B L E  1  Cytotoxicity of different corticosteroids on keratinocyte 






Hydrocortisone- 17- butyrate 340.9 ± 20.3 246.4 ± 29.4
Hydrocortisone- 17- valerate 261.3 ± 28.9 314.3 ± 52.1
Triamcinolone acetonide 194.8 ± 41.6 259.5 ± 24.3





Clobetasol- 17- propionate 32.3 ± 0.9 40.3 ± 2.1
Susceptibility of FMB6 and NOF monolayers to the cytotoxic effects of 
corticosteroids was evaluated by measuring the half maximal inhibitory 
concentration (IC50) for each corticosteroid, using an MTT assay, 72 h after 
exposure.
F I G U R E  2  Permeation of oral mucosal equivalents (OMEs) by 
corticosteroids. Permeation of tissue (A) and receptive media (B) 
was measured after 1 h of exposure to clobetasol- 17- propionate (CP), 
betamethasone- 17- valerate (BV), and hydrocortisone- 17- valerate (HV) 
(all 5 µM). Data are expressed as mean ±SD of three independent 
experiments. Statistics were performed using one- way ANOVA with 
Tukey's post- hoc multiple comparisons test; ***P < 0.001.
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found to accumulate in receptive medium, and the concentra-
tion was variable, with 5.3 ± 9.2 nM CP detected after 1 h 
(Figure 3B). As the patch containing 20  µg of CP showed 
the best permeation of this corticosteroid, a time– response 
course was performed to investigate if more CP penetrated 
with increased duration of exposure. No increase in CP con-
centration was found in tissue or receptive medium when the 
patch was applied topically for 4 h but a significant increase 
of CP was observed when the exposure time was increased 
to 24 h, with 0.94 ± 0.16 nM mg– 1 of CP found in tissue and 
95 ± 6.4 nM CP found in receptive medium, demonstrating 
that a longer contact time of the patch allows a larger quantity 
of CP to be released (Figure 3C,D).
Delivery of CP from mucoadhesive patch into 
an OME OLP- like model
To evaluate activity of CP once delivered through the OME, 
a T- cell inflammatory OME was developed. Jurkat cells 
treated with PHA and PMA secreted IL- 2 in a time- dependent 
manner, with maximal secretion (1626.3  ±  311.4  pg  ml– 1) 
achieved after 24 h. Therefore, following 2 h of stimulation, 
activated Jurkat cells were added to the basolateral compart-
ment, then CP (20  µg) in patch or liquid form was added 
topically to the OLP- like model and the concentrations of 
CP reaching the Jurkat cells in the receptive medium were 
determined after 4, 8, and 24 h. We found that CP, delivered 
from a patch, accumulated in a time- dependent manner, from 
0.016 ± 0.0017 µM at 4 h, to 0.032 ± 0.0035 µM (P < 0.01) 
at 8  h, and to 0.075  ±  0.0029  µM (P  <  0.001) at 24  h. 
Delivery of CP in liquid form resulted in significantly higher 
concentrations of CP in receptive medium than when CP was 
delivered via the patch; similarly to patch delivery, the con-
centration of CP also increased in a time- dependent manner 
when delivered in liquid form. After 4 h, 0.49 ± 0.025 µM 
CP was found to have penetrated the model to the basolateral 
compartment, with a significant increase to 1.2 ± 0.036 and 
2.3 ± 0.1 µM CP after 8 and 24 h, respectively (Figure 4A,B). 
Release of IL- 2 from activated Jurkat cells was significantly 
decreased in a time- dependent manner in response to treat-
ment with CP, delivered either as liquid or from a patch, 
compared to treatment with a placebo patch or with medium 
alone (Figure 4C).
DISCUSSION
The use of full- thickness OMEs in research has increased in 
recent years as a result of the many advantages they offer 
over monolayer cell culture. The use of immortalized cells 
in OMEs dispenses with the requirement for a continual 
supply of oral tissue for primary cell isolation, but the struc-
tural and biophysical properties of these models still need 
to be validated. We previously showed that OMEs based 
on FNB6- TERT2 immortalized oral keratinocytes display 
F I G U R E  3  Permeation of oral mucosal equivalents (OMEs) and the receptive medium by patch- formulated clobetasol- 17- propionate (CP), 
according to concentration of CP (A, B) and duration of exposure to the patch (C, D). Permeation of OMEs (A) and the corresponding receptive 
media (B) by 1, 5, and 20 µg of CP (from a loaded patch) was stopped after 1 h, and the levels of CP in tissue and the concentration of CP in 
receptive media were measured. Permeation of tissue (C) and receptive media (D) by CP (from a patch containing 20 µg of CP) was assessed after 
1, 4, and 24 h. Data are expressed as mean ±SD of three independent experiments. Statistics were performed using one- way ANOVA with Tukey's 
post- hoc multiple comparisons test; *P < 0.05.
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differentiation and proliferation marker profiles similar to 
those of native human oral mucosa (20). Further charac-
terization now shows that these OMEs adhere tightly to the 
connective tissue via hemidesmosomes and display abun-
dant cell– cell contacts, such as E- cadherin- containing des-
mosomes, and, for the first time in OMEs, claudin- 4 tight 
junctions, which are the major determinant of paracellular 
permeability (26). Interestingly, claudin- 4 expression was 
also localized to the keratinocyte nuclei in OMEs and human 
oral mucosa. This expression pattern has not been reported 
in oral mucosa previously, although both claudins 1 and 4 
have been shown to localize to the nucleus in colon and en-
dometrial cells, respectively, where they are believed to be 
involved in the transcriptional control of E- cadherin expres-
sion (27).
The presence of an effective epithelial permeability 
barrier was further substantiated by TEER analysis of the 
OME in the present study, which revealed a higher value 
(156 ± 11 Ω cm– 2 on day 20) than those found for multilay-
ered primary oral keratinocyte- only (134.8 ± 7.0 Ω cm– 2) 
(28)) or TR146 oral cancer cell (68.2 ± 2.3 Ω cm– 2) mod-
els (29)). Furthermore, FNB6- based OMEs were more 
permeable to 3- kDa dextran than to 70- kDa dextran, a 
finding similar to that for porcine buccal mucosa for 
which dextran permeability was shown to occur via the 
paracellular route (30). Taken together, our data show that 
FNB6- based OMEs display an appropriate permeability 
barrier and therefore are ideally suited for use in drug- 
delivery studies.
Corticosteroids, often used for the topical treatment of 
OLP, are categorized based on their potency using the va-
soconstrictor or psoriasis assay, the gold standards in deter-
mining the efficacy and anti- inflammatory actions of these 
drugs (31,32). However, in vitro cytotoxicity assays based 
on reduction of tetrazolium dyes are used to measure irrita-
tion of tissue- engineered skin by compounds (Organisation 
for Economic Co- operation guideline 3 and European Centre 
for the Validation of Alternative Methods) and hence may 
be useful for assessing corticosteroid potency in vitro. Based 
on IC50 values, we found corticosteroid potency on oral ke-
ratinocyte monolayers to occur in the order (high to low) 
CP>BU>BD>BV>TA>HV>HB, which is broadly in agree-
ment with current corticosteroid potency criteria for both 
British and US national formularies (33,34). Interestingly, 
IC50 values were much higher for OMEs than for monolay-
ers, with the difference probably being the stratified nature 
of OMEs and differences in expression of xenobiotic me-
tabolizing enzymes that are potentially increased in three- 
dimensional compared with two- dimensional cell culture, as 
observed for skin (35,36).
When applied to OMEs, significantly more CP than BV 
or HV was found to accumulate in the mucosa, whereas HV 
permeated most quickly though the OME into the receptive 
medium of the transwell culture system. The physicochemi-
cal properties of corticosteroids dramatically influence their 
absorption by tissue. In general, molecules with a molecular 
F I G U R E  4  Permeation of receptive medium by clobetasol- 17- 
propionate (CP) from a patch loaded with 20 µg of CP (A) and from a 
solution also containing 20 µg of CP (B) was assessed after 1, 4, and 
24 h. (C) Oral mucosal equivalents (OMEs) containing activated T- 
cells were treated with medium alone (control), placebo (patch only), a 
patch loaded with 20 µg of CP (loaded- patch), or a solution containing 
20 µg of CP (solution). After 4, 8, and 24 h, permeation of CP was 
evaluated as the amount of interleukin- 2 (IL- 2) released from activated 
T- cells. Data are expressed as mean ±SD of three independent 
experiments. Statistics were performed using one- way ANOVA 
with Tukey's post- hoc multiple comparisons test compared with all 
groups (A, B) or the medium- only control (C); *P < 0.05, **P < 0.01, 
***P < 0.001.
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mass of <0.5 kDa, such as corticosteroids, are easily trans-
ported through stratified epithelium (37). Esterification and 
addition of functional groups, such as propionate, enhances 
corticosteroid lipophilicity, increasing their absorption by 
tissue and enabling retention within the mucosa (38), which 
may explain why CP exhibited higher accumulation in tissue 
than BV and HV.
With high potency and increased retention in tissue, CP 
is frequently the choice for the therapeutic management of 
OLP (1), and so we selected this corticosteroid for incor-
poration into a novel electrospun mucoadhesive oral patch 
intended for localized, unidirectional delivery to the oral 
mucosa (25). Upon release from oral patches after 1 h, ac-
cumulation of CP in OMEs was dose- dependent, whereas 
accumulation of CP in the receptive medium was only ob-
served for the oral patches loaded with 20  µg of CP. In 
addition, following application to OMEs of oral patches 
loaded with 20  µg of CP, accumulation of CP increased 
over 24 h, both within the tissue and in the receptive me-
dium, indicating that therapeutic levels of CP are most 
likely to be achieved by a patch containing 20 µg of CP. A 
similar trend, of accumulation of CP in tissue following use 
of these patches, was observed in porcine oral mucosa (25). 
Studies using other nanoparticle drug- delivery systems 
similarly showed increased accumulation of CP in porcine 
skin epidermis, particularly in the stratum corneum, over a 
6- h period, although in these studies no CP was detected in 
the receptive medium of the Franz chamber (39,40). These 
studies indicate that CP may preferentially accumulate in 
the most apical, keratinized surfaces of skin, whereas in 
non- keratinized epithelium (such as the buccal mucosa), 
CP is free to penetrate into and across the epithelium. More 
CP was observed in the OMEs and receptive medium over 
24 h when applied in liquid form than in patch form. In the 
soluble form, CP is freely mobile, which allows fast and 
direct paracellular absorption, whereas in the electrospun 
patch, CP is held within the polymer fibres in an amor-
phous form, and hydration and collapse of the polymer 
complex is required for CP to be released (25). Therefore, 
patch- loaded drugs tend to be delivered at lower levels, and 
more slowly, than drugs in free solution (12,41). Indeed, 
the ability to control the rate of drug release over time is a 
distinct advantage for treating oral lesions.
T- cells are the main protagonists in mediating pathogen-
esis in OLP. Interleukin- 2 is amongst a number of important 
cytokines that are implicated in the disease process and it 
drives T- cell activation in an autocrine manner via the IL- 2 
receptor. High levels of IL- 2 have been reported in OLP le-
sions (42,43), whilst corticosteroids decrease expression of 
the IL2 gene and secretion of the IL- 2 protein by interfer-
ing with the transcription factors nuclear factor of activated 
T- cells, activator protein 1, and nuclear factor kappa- light- 
chain- enhancer of activated B cells (44- 47), hence the use 
of corticosteroids in treatment of OLP. Here, we used Jurkat 
T- cells as a rudimentary in vitro model cell system to assess 
if the immunosuppressive effects of CP are retained when 
it is released from the mucoadhesive patch. Incubation of 
Jurkat cells with a combination of PHA and PMA directly 
activates the protein kinase C signalling pathway, increasing 
transcription of IL2 and secretion of IL- 2 without the need 
for T- cell- receptor engagement (48). The efficiency of CP 
in reducing IL- 2 levels secreted by PHA/PMA- activated T- 
cells residing in the basolateral transwell chamber of the in 
vitro model of OLP was comparable between patch- loaded 
CP and that delivered in solution, despite more CP entering 
the basolateral lower chamber when administered by solu-
tion than by patch. Therefore, it appears that the smaller 
amount of CP delivered from the patch was still sufficient to 
inhibit transcription of IL2 in stimulated T- cells, reflecting 
the high potency of CP.
A potential limitation of this study is the use of the 
Jurkat T- cell lymphoblast cell line and its artificial acti-
vation using chemical stimulants. Although useful in this 
system as a lymphocyte source of IL- 2 production, these 
cells do not fully replicate the T- helper 1 cell phenotype 
that dominates in OLP, let alone the other T- cell sub-
sets present in these lesions. Further in- depth analysis of 
patch- delivered CP- mediated therapy would require more 
advanced tissue- engineered OLP models containing ap-
propriate T- cell- receptor- complex- activated, T- helper 
1- polarized primary T- cells. Such systems are currently 
under development. The experiments outlined in this study 
were also performed over a relatively short period of time 
and OLP is treated over a prolonged period of time, so ex-
amination of the long- term effects of patch- delivered ther-
apy is warranted in future studies.
We chose to incubate the OME T- cell model with a muco-
adhesive patch for 24 h because in this model the CP has to 
penetrate through the entire thickness of the OME and poly-
carbonate filter to reach the activated T- cells in the receptive 
medium, a distance of approximately 700 μM. It could be ar-
gued that this is a considerable length of time for a patch to be 
in contact with the oral mucosa for drug delivery. However, 
it must be noted that in patients with OLP, the target lympho-
cytes are located between the basal or suprabasal keratino-
cytes and just below the basement membrane in the lamina 
propria in mucosal tissue, which often has a denuded epithe-
lium. Therefore, in these patients CP incorporated within an 
oral patch may only need to penetrate 30– 40 μM to reach its 
target site, which thus can be reached within much shorter 
time periods than in the OME model described in the present 
study.
It is difficult to compare the mucoadhesive system used 
this study directly with other steroid- containing delivery 
formulations. Other experimental systems are scarce (8,49), 
with most studies focussed on combining corticosteroids 
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with Orabase (9- 11,50,51). The majority of these studies 
are centred on clinical trials and contain little or no data on 
preclinical or in vitro evaluation, such as drug- release pro-
files or tissue penetration. The recently published Cochrane 
Systematic Review suggests that adhesive gel- based corti-
costeroids do offer better treatment than placebo, although 
the authors concede that the small numbers of patients in 
most studies make the confidence in this finding low (7). To 
date, the data generated for the mucoadhesive oral patches 
described in this study are preclinical, making any compari-
sons with the Orabase formulations problematical. However, 
our mucosal patch delivery system has very recently com-
pleted phase II clinical trials (clinicaltrials.gov/show/
NCT03592342), which will enable a direct comparison with 
other current formulations.
In conclusion, to the best of our knowledge, this is the 
first study to show the successful transmucosal delivery of 
a corticosteroid using electrospun patch technology, and im-
portantly, to confirm that the drug delivered retains its anti- 
inflammatory activity against activated T- cells. This new 
mucoadhesive patch technology can deliver therapy directly 
to diseased oral tissue and therefore holds great promise for 
targeted, localized delivery for the treatment of OLP or for 
the delivery of other agents, such as anaesthetics or analge-
sics, which require specific, controlled delivery directly to 
oral tissue. The development of mucoadhesive patches will 
be further enhanced by improved preclinical screening using 
validated tissue- engineered OMEs based on immortalized 
keratinocytes that are more standardized and accessible to 
the scientific community.
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